VRXA (Veraxa Biotech Holding AG) EPS without NRI: $-0.58 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRXA Veraxa Biotech Holding AG VRXA
6 GF Score
Price $1.77
! 2 Warning Signs
View Full Analysis

What is Veraxa Biotech Holding AG EPS without NRI?

Veraxa Biotech Holding AG VRXA -10.66% 6 EPS without NRI is $-0.58 as of Dec. 2025. GuruFocus rates VRXA with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 1,166 Biotechnology companies, Veraxa Biotech Holding AG ranks worse than 85763.21% on this metric.

Veraxa Biotech Holding AG's earnings per share without non-recurring items for the six months ended in Dec. 2025 was $-0.26. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.58.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Veraxa Biotech Holding AG's EPS without NRI or its related term are showing as below:

VRXA's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.2
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Veraxa Biotech Holding AG's EPS (Diluted) for the six months ended in Dec. 2025 was $-0.27. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.58.

Veraxa Biotech Holding AG's EPS (Basic) for the six months ended in Dec. 2025 was $-0.27. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.58.


Veraxa Biotech Holding AG  (NAS:VRXA) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Veraxa Biotech Holding AG EPS without NRI Related Terms


Veraxa Biotech Holding AG EPS without NRI Historical Data

* Premium members only.

The historical data trend for Veraxa Biotech Holding AG's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veraxa Biotech Holding AG EPS without NRI Chart

Veraxa Biotech Holding AG Annual Data
Trend Dec23 Dec24 Dec25
EPS without NRI
-0.13 -0.22 -0.58

Veraxa Biotech Holding AG Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
EPS without NRI 0.00 -0.09 -0.14 -0.32 -0.26

VRXA vs TTRX, IRD, IFRX: EPS without NRI Comparison

For the Biotechnology subindustry, Veraxa Biotech Holding AG's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veraxa Biotech Holding AG PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veraxa Biotech Holding AG's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Veraxa Biotech Holding AG's PE Ratio without NRI falls into.


VRXA
6GF Score
Veraxa Biotech Holding AG VRXA
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veraxa Biotech Holding AG EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-0.58 mean?
Veraxa Biotech Holding AG (VRXA) has a EPS without NRI of $-0.58 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Veraxa Biotech Holding AG and its competitors. According to the industry distribution chart, Veraxa Biotech Holding AG ranks #999999 out of 1166 companies in the Biotechnology industry.
Is Veraxa Biotech Holding AG's EPS without NRI too high?
Veraxa Biotech Holding AG's current EPS without NRI is $-0.58. Based on the distribution chart, Veraxa Biotech Holding AG ranks #999999 out of 1166 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Veraxa Biotech Holding AG has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's EPS without NRI compare to TTRX and IRD?
According to the Biotechnology industry distribution chart, Veraxa Biotech Holding AG ranks #999999 out of 1166 companies for EPS without NRI. This places Veraxa Biotech Holding AG in the lower half of its industry. The industry median EPS without NRI is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.20, based on 1,166 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Veraxa Biotech Holding AG and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veraxa Biotech Holding AG's current EPS without NRI is $-0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (VRXA) has a current EPS without NRI of $-0.58. The current EPS without NRI is $-0.58. Veraxa Biotech Holding AG's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Veraxa Biotech Holding AG (VRXA), the current EPS without NRI is $-0.58 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veraxa Biotech Holding AG Business Description

Other Exchanges J8L0:Germany
Address Talacker 35, Zurich, CHE, 8001
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
6GF Score

Get the complete analysis for VRXA

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.77
Price